STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Public ClinicalTrials.gov record NCT05490563. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Placebo Controlled, Trial to Assess Safety and Efficacy of SLS-005 (Trehalose Injection, 90.5 mg/mL for Intravenous Infusion) for the Treatment of Adults With Spinocerebellar Ataxia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 2b/3 double blind, randomized, placebo-controlled trial to assess safety and efficacy of SLS-005 (trehalose injection, 90.5 mg/mL for intravenous infusion) for the treatment of adults with spinocerebellar ataxia).
Study identification
- NCT ID
- NCT05490563
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2022
- Primary completion
- Nov 23, 2023
- Completion
- Nov 23, 2023
- Last update posted
- Apr 23, 2024
2022 – 2023
United States locations
- U.S. sites
- 7
- U.S. states
- 7
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA | Los Angeles | California | 90095 | — |
| UCHealth Neurosciences Center - Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| University of South Florida | Tampa | Florida | 33612 | — |
| Harvard Medical School - Beth Israel Deaconess Medical Center (BIDMC) | Boston | Massachusetts | 02215-5395 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| UT Southwestern Medical Center | Dallas | Texas | 75390 | — |
| Swedish Neuroscience Specialists - Movement Disorders | Seattle | Washington | 98122 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 16 non-U.S. sites.
Recently updated Spinocerebellar Ataxia Type 3 trials
Other public records listing Spinocerebellar Ataxia Type 3. Sorted by last update posted; newest first. Not a recommendation.
- NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias Recruiting
- NCT03701399: Troriluzole in Adult Participants With Spinocerebellar Ataxia Active, not recruiting
- NCT01793168: Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting
- NCT05826171: Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05490563, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2024 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05490563 live on ClinicalTrials.gov.